Cadrenal Therapeutics, Common Stock Buy Hold or Sell Recommendation
| CVKD Stock | 19.09 1.64 9.40% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cadrenal Therapeutics, Common is 'Hold'. Macroaxis provides Cadrenal Therapeutics, buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CVKD positions.
Check out Cadrenal Therapeutics, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Cadrenal and provide practical buy, sell, or hold advice based on investors' constraints. Cadrenal Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
Cadrenal |
Execute Cadrenal Therapeutics, Buy or Sell Advice
The Cadrenal recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cadrenal Therapeutics, Common. Macroaxis does not own or have any residual interests in Cadrenal Therapeutics, Common or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cadrenal Therapeutics,'s advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Good | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cadrenal Therapeutics, Trading Alerts and Improvement Suggestions
| Cadrenal Therapeutics, is way too risky over 90 days horizon | |
| Cadrenal Therapeutics, appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (10.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cadrenal Therapeutics, generates negative cash flow from operations | |
| Cadrenal Therapeutics, has a poor financial position based on the latest SEC disclosures | |
| About 32.0% of the company shares are held by company insiders | |
| Latest headline from seekingalpha.com: Cadrenal Therapeutics GAAP EPS of -8.73 misses by 1.14 |
Cadrenal Therapeutics, Returns Distribution Density
The distribution of Cadrenal Therapeutics,'s historical returns is an attempt to chart the uncertainty of Cadrenal Therapeutics,'s future price movements. The chart of the probability distribution of Cadrenal Therapeutics, daily returns describes the distribution of returns around its average expected value. We use Cadrenal Therapeutics, Common price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cadrenal Therapeutics, returns is essential to provide solid investment advice for Cadrenal Therapeutics,.
| Mean Return | 0.80 | Value At Risk | -8.49 | Potential Upside | 11.59 | Standard Deviation | 5.71 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cadrenal Therapeutics, historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cadrenal Therapeutics, Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cadrenal Therapeutics, or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cadrenal Therapeutics,'s price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cadrenal stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.92 | |
β | Beta against Dow Jones | 1.21 | |
σ | Overall volatility | 5.75 | |
Ir | Information ratio | 0.16 |
Cadrenal Therapeutics, Volatility Alert
Cadrenal Therapeutics, Common exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cadrenal Therapeutics,'s stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cadrenal Therapeutics,'s stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cadrenal Therapeutics, Fundamentals Vs Peers
Comparing Cadrenal Therapeutics,'s fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cadrenal Therapeutics,'s direct or indirect competition across all of the common fundamentals between Cadrenal Therapeutics, and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cadrenal Therapeutics, or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cadrenal Therapeutics,'s fundamental indicators could also be used in its relative valuation, which is a method of valuing Cadrenal Therapeutics, by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cadrenal Therapeutics, to competition |
| Fundamentals | Cadrenal Therapeutics, | Peer Average |
| Return On Equity | -1.25 | -0.31 |
| Return On Asset | -0.71 | -0.14 |
| Current Valuation | 26.74 M | 16.62 B |
| Shares Outstanding | 1.78 M | 571.82 M |
| Shares Owned By Insiders | 32.37 % | 10.09 % |
| Shares Owned By Institutions | 5.95 % | 39.21 % |
| Number Of Shares Shorted | 41.48 K | 4.71 M |
| Price To Book | 9.12 X | 9.51 X |
| EBITDA | (10.96 M) | 3.9 B |
| Net Income | (10.65 M) | 570.98 M |
| Total Debt | 2.68 M | 5.32 B |
| Book Value Per Share | 2.76 X | 1.93 K |
| Cash Flow From Operations | (7.36 M) | 971.22 M |
| Short Ratio | 0.71 X | 4.00 X |
| Earnings Per Share | (6.73) X | 3.12 X |
| Target Price | 35.67 | |
| Number Of Employees | 4 | 18.84 K |
| Beta | 1.45 | -0.15 |
| Market Capitalization | 34.03 M | 19.03 B |
| Total Asset | 10.12 M | 29.47 B |
| Retained Earnings | (25.72 M) | 9.33 B |
| Working Capital | 7.67 M | 1.48 B |
| Net Asset | 10.12 M |
Note: Acquisition by Ferguson James J. Iii of 60000 shares of Cadrenal Therapeutics, at 19.75 subject to Rule 16b-3 [view details]
Cadrenal Therapeutics, Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cadrenal . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cadrenal Therapeutics, Buy or Sell Advice
When is the right time to buy or sell Cadrenal Therapeutics, Common? Buying financial instruments such as Cadrenal Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cadrenal Therapeutics, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Data Storage Thematic Idea Now
Data Storage
Companies making data storages or providing data storage services. The Data Storage theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Data Storage Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cadrenal Therapeutics, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.